NIKKEI 225
27,857.03 +36.63 (+0.13%) HANG SENG
19,518.29 +842.94 (+4.51%) CRUDE OIL
77.34 +0.41 (+0.53%) GOLD FUTURES
1,782.20 +0.90 (+0.05%) DOW
33,947.10 -482.78 (-1.40%) BTC-GBP
13,944.19 -217.40 (-1.54%)
Genfit S.A. (0QT6.IL)
| Previous close | 3.4480 |
| Open | 0.0000 |
| Bid | 3.3640 x 0 |
| Ask | 3.5360 x 0 |
| Day's range | 3.4120 - 3.4390 |
| 52-week range | 2.7800 - 4.7280 |
| Volume | |
| Avg. volume | 9,241 |
| Market cap | 171.863M |
| Beta (5Y monthly) | 1.07 |
| PE ratio (TTM) | 4.31 |
| EPS (TTM) | 0.8000 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Globe Newswire
GENFIT Pipeline Day Highlights Diverse Product Portfolio in Underserved Liver Diseases
Phase 3 data for elafibranor in primary biliary cholangitis (PBC) expected in 2Q23Expanded pipeline now covers five therapeutic areas with high unmet medical need via six independent programs exploring the potential of differentiated mechanisms of actionA regular stream of new clinical data expected over the next few years across the spectrum of development stages (Phase 1, Phase 2, Phase 3)Aggregated global market size potential >$15bn1, distributed among acute on-chronic liver failure (ACLF) w
- Globe Newswire
GENFIT Reports Third Quarter 2022 Financial Information
Cash and cash equivalents: €163.6 million as of September 30, 2022 Lille, France; Cambridge, MA; November 10, 2022 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with severe chronic liver diseases, today announced its cash position as of September 30, 2022 and revenue for the first nine months of 20221. Cash Position As of September 30, 2022, the Company’s cash and cash equivalents amounted to €163.6 million compared with
- Globe Newswire
GENFIT Announces Compelling Results for Next-Generation Non-Invasive Diagnostic Technology NIS2+™ in NASH to be Presented at the AASLD Liver Meeting®
NIS2+™ developed and validated as an optimization of NIS4® technology for the detection of patients with at-risk NASHData demonstrate robust and improved clinical performance of NIS2+™ allowing an efficient identification of at-risk NASH, irrespective of patient characteristics such as age, sex and Type-2 diabetesNIS2+™’s analytical improvement allows for larger scale implementation in clinical practice and clinical trialsThree posters to be presented at AASLD Liver Meeting® Lille (France), Camb
